| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8785449 | Brachytherapy | 2017 | 10 Pages |
Abstract
Despite worse patient prognostic features, MR-ISBT was associated with a significantly better (100%) 3-year local control, comparable survival, and improved DFI rates compared to CT. Toxicities did not differ compared to CT-ISBT patients. Tumor grade contributed as the most significant predictor for survival. Larger prospective studies are needed to assess the impact of MR-ISBT on survival outcomes.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Sophia C. Kamran, Matthias M. Manuel, Paul Catalano, Linda Cho, Antonio L. Damato, Larissa J. Lee, Ehud J. Schmidt, Akila N. Viswanathan,